NPM1 and acute myeloid leukemia: Although the standard of care currently for AML is the “7 + 3” regimen, consideration is needed for NPM1-mutated AML co-mutated with; FLT3-ITD, for which FLT3 inhibitors are used or SYK inhibitors may also be used as in vivo studies have inferred SYK involvement in FLT3 activation.